[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"First Affiliated Hospital, Sun Yat-Sen University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":603},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,35,0,25,[9,45,67,93,114,131,145,162,189,214,237,266,290,314,335,365,390,413,433,455,478,504,529,552,578],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100494686","phase-4-icodextrin-postpones-the-shift-of-low-dose-to-full-dose-dialysis-in-the-first-year-of-incremental-peritoneal-dialysis-100494686",false,"NCT05721404","Icodextrin Postpones the Shift of Low Dose to Full Dose Dialysis in the First Year of Incremental Peritoneal Dialysis","Icodextrin Postpones the Shift of Low Dose to Full Dose Dialysis in the First Year of Incremental Peritoneal Dialysis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years old;\n* The estimated glomerular filtration rate (eGFR) ≥ 3ml\u002Fmin·1.73m2 when enrolled;\n* The 24-hour urine volume ≥ 500ml when enrolled;\n* The patient or his lawful representative is able to receive and complete training of home peritoneal dialysis;\n* Patients were able to follow the follow-up schedule and other requirements of the study;\n* Patients can come to the peritoneal dialysis center for regular follow-up (once every 2 months or more);\n* Participants were expected to remain on peritoneal dialysis for at least 13 months;\n* Patients with good compliance;\n* Informed consent was obtained.\n\nExclusion Criteria:\n\n* Treated with both peritoneal dialysis and hemodialysis;\n* Patients who have previously received a kidney transplant and have been receiving immunosuppressive therapy;\n* Contraindications to bioelectrical impedance analysis (BIA) testing (e.g., amputation, use of a pacemaker or prosthesis);\n* Allergy to Icodextrin, starch and starch products, or suffer from glycogen storage disease;\n* Contraindications for the use of icodextrin;\n* HIV-positive participants;\n* Patients with tumors or other serious diseases have a life expectancy of less than one year;\n* Mental illness that interferes with the patient's understanding of the test requirements and completion of the test process;\n* Chronic wasting diseases such as tuberculosis, cirrhosis, hematological or other malignancies;\n* Patients who are pregnant, intending to become pregnant, or breastfeeding during the study period;\n* The patients had a history of drug abuse or alcoholism 2 years before the screening period;\n* Patients who are unwilling or not expected to fully comply with the visits and evaluations required by the protocol;\n* Patients who, in the investigator's judgment, have other serious or acute medical conditions that may prevent them from participating in the study.","ALL","18 Years",{"count":20,"type":21},194,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","We hypothesize incremental peritoneal dialysis (incremental PD) protocol with icodextrin solution will help patients to achieve adequate ultrafiltration and adequate dialysis with less glucose exposure by manipulating a low frequency of exchanges, therefore prolong the time from incremental protocol to full dose protocol (Full dose dialysis is defined as a dialysis dose of more than 8 L (4 exchanges of 2 L) per day). The goal of this clinical trial is to investigate the effect of icodextrin postponing the shift of low dose to full dose dialysis in the first year of incremental peritoneal dialysis. The main questions are:\n\n* The effect of icodextrin on the shift of low dose to full dose dialysis in the first year in patients on incremental peritoneal dialysis.\n* The effect of icodextrin on clinical outcomes in patients on incremental peritoneal dialysis, such as the first episode of peritonitis, the incidence of anuria, the first incidence of hospitalization, technical failure, all cause mortality, cardiovascular disease free survival and the quality of life.\n\nParticipants will be 1:1 randomized to the ICO (icodextrin) arm and CON (control) arm. Both arms patients will be followed every 2 months for fluid status by bioimpedance analysis. An extracellular water \u002Ftotal body water (ECW\u002FTBW) ≥ 0.40 or edema is defined as overhydration (OH). The OH patients in the ICO arm will be prescribed icodextrin (Extraneal) for long night dwell to improve fluid overload till their re-measurement of ECW\u002FTBW \\\u003C 0.40 or edema disappeared. The OH patients in the CON arm will be prescribed hypertonic Dextrose solution for long night dwell to improve fluid overload till their ECW\u002FTBW \\\u003C 0.40 or edema disappeared.\n\nResearchers will compare the time of transferring from low dose PD to full dose and the clinical outcomes in the first year between the patients in ICO and CON groups to see the effect of icodextrin on the shift of low dose to full dose dialysis and clinical outcomes in the first year in patients on incremental peritoneal dialysis. Successful completion of the study will advance our strategy of incremental PD and help to prolong the shift from incremental to full dose dialysis, and offer new opportunities for the development of an effective and economical therapy for PD patients with residual kidney function (RKF)",[27],"Peritoneal Dialysis",[29,30,31],"peritoneal dialysis","incremental peritoneal dialysis","icodextrin","RECRUITING","2026-06-26",{"date":35,"type":36},"2026-06-29","ACTUAL",{"date":38,"type":36},"2023-05-24",{"date":40,"type":21},"2027-12-31",{"name":42,"class":43},"First Affiliated Hospital, Sun Yat-Sen University","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":44},"100636172","rapid-construction-of-tissue-engineered-skin-for-repairing-difficult-to-heal-wounds-100636172","NCT07562230","Rapid Construction of Tissue-engineered Skin for Repairing Difficult-to-heal Wounds","Rapid Construction of Tissue-engineered Skin for Repairing Difficult-to-heal Wounds: A Multicenter Real-world Study","Inclusion Criteria:\n\n* All-age population\n\nWounds requiring surgical repair （single area 10-100 cm²）： acute wounds （burns, traumatic defects, post-scar resection） OR chronic wounds （diabetic foot ulcers, pressure injuries, vascular ulcers）\n\nCompleted wound bed preparation （no necrotic tissue, infection controlled）\n\nSigned informed consent and agreement to use tissue-engineered materials and long-term follow-up\n\nExclusion Criteria:\n\n* History of allergy to allogeneic\u002Fxenogeneic tissue-engineered scaffolds or collagen materials\n\nSevere immunosuppression （HIV\u002FAIDS, long-term immunosuppressant use）\n\nMalignant tumors, uncontrolled systemic infection （CRP \\> 50 mg\u002FL）， or organ failure （Child-Pugh Class C）\n\nMental illness preventing compliance with treatment or follow-up\n\nPregnant or lactating women",{"count":53,"type":21},1000,[55],"NA","This multicenter real-world study evaluates the efficacy and safety of a novel technique for rapid intraoperative construction of tissue-engineered skin using autologous epidermal stem cells （EpiSCs） for repairing difficult-to-heal wounds. Eligible patients are randomized to receive either: （1） the experimental intervention （rapidly constructed EpiSCs-loaded scaffold combined with split-thickness skin graft via one-step or two-step procedure）， or （2） control intervention （acellular scaffold combined with split-thickness skin graft）. The primary outcome is the complete wound healing rate at 4 weeks post-surgery. Secondary outcomes include wound recurrence, scar quality （VSS\u002FPOSAS）， functional recovery （sweat test）， mortality, amputation rate, and safety profile.",[58],"Wounds and Injuries \u002F Mortality","2026-04-27",{"date":61,"type":36},"2026-05-01",{"date":63,"type":36},"2026-01-01",{"date":65,"type":21},"2030-12-01",{"name":42,"class":43},{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":44},"100617763","phase-3-deb-tace-vs-ctace-in-hcc-after-tips-100617763","NCT07322848","DEB-TACE vs cTACE in HCC After TIPS","Drug Eluting Beads Transarterial Chemoembolization Versus Conventional Transarterial Chemoembolization for Beyond-Milan-Criteria Hepatocellular Carcinoma After Transjugular Intrahepatic Portosystemic Shunt: A Phase 3, Open Label, Multicenter, Randomized Controlled Trial","UPGRADE","Inclusion Criteria:\n\n1. histologically or clinically confirmed primary hepatocellular carcinoma, beyond Milan criteria (single lesion \\>5 cm OR ≥3 lesions with at least one ≥3 cm). At least one intrahepatic measurable lesion with tumor burden ≤50%, no distant metastasis. No prior antitumor therapy within 12 months before enrollment.\n2. underwent TIPS procedure for secondary prevention of variceal bleeding or refractory ascites. Confirmed patent TIPS at 1-month follow-up with portosystemic blood flow visible throughout the shunt and Doppler velocity \\> 60 cm\u002Fs.\n3. child-Pugh class A or B.\n4. estimated survival ≥3 months.\n5. adequate organ function:Neutrophils ≥1.5 × 10⁹\u002FL; Platelets ≥50 × 10⁹\u002FL; Hemoglobin ≥90 g\u002FL; Serum albumin ≥30 g\u002FL; Bilirubin ≤50 μmol\u002FL; AST\u002FALT ≤5 × upper limit of normal (ULN), ALP ≤4 × ULN; INR ≤2.3; Creatinine ≤1.5 × ULN.\n\nExclusion Criteria:\n\n1. diffuse hepatic infiltration, unassessable lesions on imaging, or tumor burden \\>50%.\n2. simultaneous portal vein branch tumor thrombus or main portal vein tumor thrombus.\n3. underwent liver transplantation or antitumor therapy after TIPS placement.\n4. contraindications to TACE (e.g., portosystemic shunt, hepatofugal blood flow, significant atherosclerosis).\n5. presence of brain metastases.\n6. Allergy to contrast agents.\n7. pregnancy, breastfeeding, or planning pregnancy within 2 years.\n8. co-infection with HIV or syphilis.\n9. concurrent other malignancy or history of other malignancy within the past 5 years.\n10. severe cardiac, renal, or other organ dysfunction.\n11. active clinically severe infection \\> Grade 2 (per NCI-CTC v5.0).\n12. psychiatric\u002Fpsychological conditions that may impair informed consent.\n13. participation in other drug clinical trials within 12 months prior to enrollment.","75 Years",{"count":77,"type":21},206,[79],"PHASE3","This is a Phase 3, open-label, multicenter, randomized controlled clinical trial designed to evaluate the efficacy and safety of Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE) compared with Conventional Transarterial Chemoembolization (cTACE) in patients with hepatocellular carcinoma (HCC) that is beyond the Milan criteria and who have previously undergone a Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedure. The TIPS procedure is commonly performed to manage complications of portal hypertension, such as variceal bleeding or refractory ascites, in patients with cirrhosis. However, after TIPS, treatment options for HCC-particularly in cases exceeding the Milan criteria-remain limited and not well-defined in current guidelines.\n\nWhile TACE is a standard locoregional therapy for intermediate-stage HCC, its application in patients with a prior TIPS is controversial due to altered hepatic hemodynamics, which may increase the risk of liver toxicity and compromise treatment safety and efficacy. Preliminary retrospective data suggest that DEB-TACE, which uses calibrated drug-eluting microspheres, may offer a safer and more effective alternative to cTACE in this specific patient population by providing more controlled drug delivery and potentially reducing systemic and hepatic toxicity.\n\nThe primary objective of this study is to determine whether DEB-TACE improves Overall Survival (OS) compared to cTACE in patients with beyond-Milan HCC after TIPS. Secondary objectives include comparing the safety profile, Progression-Free Survival (PFS), Objective Response Rate (ORR), Disease Control Rate (DCR), and Quality of Life (QoL) between the two treatment arms.\n\nThe study aims to enroll 206 participants who will be randomly assigned in a 1:1 ratio to receive either DEB-TACE or cTACE. The trial will include a 24-month recruitment period and a 24-month treatment and follow-up phase, with a total study duration of 48 months. By directly comparing these two TACE approaches in a prospectively defined and randomized setting, this study seeks to provide high-level evidence to guide the optimal locoregional treatment strategy for HCC patients with a history of TIPS placement.",[82,83,84,85,86],"Hepatocellular Carcinoma (HCC)","TACE","TIPS","DEB-TACE","cTACE",{"date":61,"type":36},{"date":89,"type":36},"2025-12-01",{"date":91,"type":21},"2029-12-31",{"name":42,"class":43},{"id":94,"slug":95,"hasResults":12,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":100,"targetDuration":102,"studyType":103,"phases":4,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":112,"leadSponsor":113,"locationsCount":4},"100635648","cell-suspension-with-biologic-dressing-for-burn-wounds-100635648","NCT07555418","Cell Suspension With Biologic Dressing for Burn Wounds","A Prospective, Multicenter, Real-World Observational Study of Autologous Epidermal Cell Suspension Combined With Biological Dressing for Wound Repair After Dermabrasion or Surgical Debridement in Patients With Second-Degree Burns","Inclusion Criteria:\n\n* Patients with second-degree burn wounds requiring surgical dermabrasion or debridement and wound repair.\n* Age (No age restriction). For minors under 18 years, informed consent must be provided by a parent or legal guardian.\n* Stable vital signs and able to tolerate debridement and surgical procedures as confirmed by routine examinations.\n* Understand and willing to participate and able to provide signed informed consent.\n\nExclusion Criteria:\n\n* Severe uncontrolled systemic disease or acute systemic infection, or severe organ dysfunction (heart, lung, brain, etc.).\n* Psychiatric disorder that prevents compliance with treatment or follow-up.\n* Known allergy to porcine-derived materials or any component of the cell suspension preparation reagents.\n* Presence of diseases (e.g., autoimmune disease) or use of medications (e.g., high-dose immunosuppressants or corticosteroids) that may significantly affect wound healing.\n* HIV positivity, clinical diagnosis of AIDS, or absolute neutrophil count (ANC) \\\u003C 1000 cells\u002Fmm³ during screening.",{"count":101,"type":21},386,"6 Months","OBSERVATIONAL","This study is a prospective, multicenter, real-world observational study. It aims to evaluate the effectiveness and safety of a combined therapy-autologous epidermal cell suspension followed by biological dressing (porcine xenograft) coverage-for wound repair after dermabrasion or surgical debridement in patients with second-degree burns. A total of 193 patients receiving the combined therapy will be enrolled from multiple hospitals across China. Their outcomes will be compared with 193 matched patients who received conventional treatment alone (e.g., xenograft alone, autologous skin grafting, or standard dressing changes). The primary outcomes include wound healing rate at 4 weeks and time to complete wound closure. Secondary outcomes include scar assessment, pigmentation, functional recovery, quality of life, and safety. Patients will be followed for up to 6 months.",[106],"Wound Healing","NOT_YET_RECRUITING","2026-04-24",{"date":110,"type":36},"2026-04-29",{"date":61,"type":21},{"date":91,"type":21},{"name":42,"class":43},{"id":115,"slug":116,"hasResults":12,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":121,"targetDuration":102,"studyType":103,"phases":4,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":129,"leadSponsor":130,"locationsCount":4},"100635515","plasma-therapy-for-diverse-wounds-100635515","NCT07553689","Plasma Therapy for Diverse Wounds","A Prospective, Multicenter, Real-World Observational Study of a Plasma Device for Adjunctive Therapy in Acute Wounds, Chronic Wounds, Post-Grafting Wounds, and Sutured Wounds","Inclusion Criteria:\n\n* Presence of any of the following wound types: acute wounds (burns, trauma, surgical incisions, skin avulsions), chronic wounds (diabetic foot ulcers, pressure injuries, venous ulcers, radiation ulcers, burn residual wounds), post-grafting wounds (autograft or allograft, including donor and recipient sites), or sutured wounds (postoperative incisions, flap surgery, tension-reducing sutures).\n* Age ≥ 12 years (for minors under 18 years, informed consent must be provided by a parent or legal guardian).\n* Stable vital signs and able to tolerate wound treatment.\n* Willing to participate and able to provide signed informed consent.\n\nExclusion Criteria:\n\n* Active malignant tumor involving the wound area.\n* Severe systemic infection or sepsis.\n* Severe immunodeficiency or long-term use of high-dose corticosteroids.\n* Intolerance to plasma therapy or refusal to participate.\n* Pregnancy or breastfeeding.",{"count":53,"type":21},"This study is a prospective, multicenter, real-world observational study. It aims to evaluate whether adding plasma device therapy to standard wound care is effective and safe for treating different types of wounds, including acute wounds (such as burns and surgical incisions), chronic wounds (such as diabetic foot ulcers and pressure injuries), post-grafting wounds, and sutured wounds.\n\nA total of 500 patients receiving standard wound care plus plasma therapy will be enrolled from multiple hospitals across China. Their outcomes will be compared with 500 matched patients who received standard wound care alone. The main outcomes include wound healing rate at 4 weeks, time to complete wound closure, pain relief, scar formation, and any side effects. Patients will be followed for up to 6 months.",[124],"Wound Care","2026-04-23",{"date":127,"type":36},"2026-04-28",{"date":61,"type":21},{"date":91,"type":21},{"name":42,"class":43},{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":138,"targetDuration":102,"studyType":103,"phases":4,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":141,"startDateStruct":142,"completionDateStruct":143,"leadSponsor":144,"locationsCount":4},"100635330","basement-membrane-regeneration-for-wound-repair-100635330","NCT07551284","Basement Membrane Regeneration for Wound Repair","A Prospective, Multicenter, Real-World Observational Study of Autologous Basement Membrane Regeneration Technology (Epidermal Basal Cell Suspension Using Cell Sorting System) for Wound Repair in Patients Undergoing Skin Grafting, Flap Surgery, or Primary Suture","Inclusion Criteria:\n\n* Patients with wounds requiring surgical repair (skin grafting, flap surgery, or primary suture), including but not limited to: burn wounds, traumatic wounds, post-surgical excision defects (e.g., scars, pigmentation disorders, skin tumors), and chronic wounds (diabetic ulcers, venous ulcers, pressure injuries, radiation ulcers, neuropathic ulcers, burn residual wounds, etc.).\n* Age (No age restriction). For minors under 18 years, informed consent must be provided by a parent or legal guardian.\n* Stable vital signs and able to tolerate surgery as confirmed by routine examinations.\n* Understand and willing to participate and able to provide signed informed consent.\n\nExclusion Criteria:\n\n* Severe uncontrolled systemic disease or acute systemic infection, rapidly progressive or advanced disease, or severe organ dysfunction (heart, lung, brain, etc.).\n* Psychiatric disorder.\n* Presence of diseases (e.g., malignant tumor, autoimmune disease) or use of medications (e.g., high-dose corticosteroids: ≥40 mg prednisone or equivalent per day for ≥2 weeks) that may affect wound healing.\n* HIV positivity, clinical diagnosis of AIDS, or absolute neutrophil count (ANC) \\\u003C 1000 cells\u002Fmm³ during screening.\n* Pregnancy or breastfeeding.\n* Active infection or necrosis of the wound (unless controlled after debridement).",{"count":53,"type":21},"This study is a prospective, multicenter, real-world observational study. It aims to evaluate the effectiveness and safety of autologous basement membrane regeneration technology (epidermal basal cell suspension prepared using a cell sorting system) for wound repair in patients undergoing skin grafting, flap surgery, or primary suture. A total of 500 patients receiving the cell suspension therapy combined with standard surgical procedures will be enrolled from multiple hospitals across China. Their outcomes will be compared with 500 matched patients receiving standard surgical procedures alone (e.g., skin grafting, flap surgery, or suture without cell suspension). The primary outcomes include complete wound healing rate at 4 weeks (for grafted wounds) and time to complete wound closure (for sutured or flap-repaired wounds). Secondary outcomes include wound area reduction rate, recurrence rate, scar assessment (Vancouver Scar Scale), pain score (ASA), sweat function test, basement membrane integrity (histopathology with collagen IV and VII staining if clinically indicated), and safety. Patients will be followed for up to 6 months.",[106],{"date":110,"type":36},{"date":61,"type":21},{"date":91,"type":21},{"name":42,"class":43},{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":152,"targetDuration":102,"studyType":103,"phases":4,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":159,"leadSponsor":161,"locationsCount":4},"100635123","plasma-therapy-for-scar-management-100635123","NCT07548593","Plasma Therapy for Scar Management","A Prospective, Multicenter, Real-World Observational Study of a Plasma Device for the Treatment of Hypertrophic Scars, Keloids, Atrophic Scars, Postoperative Scars, and Burn Scars","Inclusion Criteria:\n\n* Clinical diagnosis of scar requiring therapeutic intervention, including but not limited to hypertrophic scar, keloid, atrophic scar, postoperative linear scar, burn scar, post-traumatic scar, or post-acne scar.\n* Scar duration ≥ 3 months, in stable or proliferative phase.\n* Age ≥ 12 years (for minors under 18 years, informed consent must be provided by a parent or legal guardian).\n* Stable vital signs and able to tolerate scar treatment.\n* Understand and willing to participate and able to provide signed informed consent.\n\nExclusion Criteria:\n\n* Active infection, ulceration, or malignant tumor involving the scar area. Severe uncontrolled systemic disease or major organ dysfunction (heart, lung, brain, etc.).\n* Psychiatric disorder that prevents compliance with treatment.\n* Presence of diseases (malignant tumor, autoimmune disease) or use of medications (high-dose corticosteroids: ≥40 mg prednisone or equivalent per day for ≥2 weeks) that may affect scar healing or assessment.\n* HIV positivity, clinical diagnosis of AIDS, or absolute neutrophil count (ANC) \\\u003C 1000 cells\u002Fmm³ during screening.\n* Pregnancy or breastfeeding.\n* Previous treatment of the scar area (e.g., laser, injection, surgery) without a washout period of ≥3 months.",{"count":153,"type":21},800,"This study is a prospective, multicenter, real-world observational study. It aims to evaluate whether adding plasma device therapy to standard scar care is effective and safe for treating various types of scars, including hypertrophic scars, keloids, atrophic scars, postoperative scars, burn scars, and post-traumatic scars. A total of 400 patients receiving standard scar care plus plasma therapy will be enrolled from multiple hospitals across China. Their outcomes will be compared with 400 matched patients who received standard scar care alone. The main outcomes include change in Vancouver Scar Scale (VSS) score, pruritus relief, pain relief, scar thickness reduction, patient satisfaction, recurrence rate at 6 months, and any side effects. Patients will be followed for up to 6 months after treatment completion.",[106],"2026-04-22",{"date":59,"type":36},{"date":61,"type":21},{"date":160,"type":21},"2026-12-31",{"name":42,"class":43},{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":170,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":172,"conditions":173,"keywords":177,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":44},"100634873","integrated-ultrasound-derived-fat-fraction-and-2d4d-heartai-for-cardiovascular-risk-management-in-patients-with-masld-100634873","NCT07545343","Integrated Ultrasound-Derived Fat Fraction and 2D\u002F4D HeartAI for Cardiovascular Risk Management in Patients With MASLD","Integration of Ultrasound-Derived Fat Fraction With 2D and 4D HeartAI for Cardiovascular Risk Management in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Observational Cohort Study","MUCHAI","Inclusion Criteria:\n\n* Adults aged 18 to 75 years\n* Diagnosis of MASLD based on imaging or biopsy\n* Presence of at least one cardiometabolic risk factor, such as BMI ≥25 kg\u002Fm², type 2 diabetes mellitus, or dyslipidemia\n* No contraindication to ultrasound imaging\n\nExclusion Criteria:\n\n* Significant alcohol consumption: \\>20 g\u002Fday for women or \\>30 g\u002Fday for men Secondary causes of hepatic steatosis, such as viral hepatitis or autoimmune liver disease\n* Known advanced heart failure (New York Heart Association class III-IV)\n* Recent cardiovascular event within 6 months\n* Pregnancy\n* Inability to complete follow-up",{"count":171,"type":21},700,"This prospective observational cohort study aims to evaluate the association between liver fat fraction measured by ultrasound-derived fat fraction (UDFF) and cardiac functional parameters assessed by 2D and 4D HeartAI in adult patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Participants will undergo baseline assessment and repeat evaluations at 6, 12, and 36 months. The study will assess the diagnostic performance of integrated UDFF-HeartAI analysis for detecting subclinical cardiac abnormalities and identify predictors of cardiovascular risk progression and major adverse cardiovascular events in patients with MASLD.",[174,175,176],"MASLD","Cardiovascular (CV) Risk","Subclinical Cardiovascular Impairments",[178,179,180,181],"Ultrasound-Derived Fat Fraction","Echocardiography","Cardiovascular Events","Major Adverse Cardiovascular Events","2026-04-16",{"date":156,"type":36},{"date":185,"type":21},"2026-06-01",{"date":187,"type":21},"2030-05-31",{"name":42,"class":43},{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":195,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":198,"conditions":199,"keywords":204,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":44},"100599663","ai-driven-multimodal-imaging-integration-for-diagnosis-and-prognostication-of-digestive-system-diseases-100599663","NCT07087418","AI-Driven Multimodal Imaging Integration for Diagnosis and Prognostication of Digestive System Diseases","Inclusion Criteria:\n\n* Patients with multimodal-confirmed diagnoses (clinical, imaging, endoscopic, and pathological) of:\n\n  * Inflammatory bowel disease (IBD; Crohn's disease or ulcerative colitis)\n  * Intestinal tuberculosis\n  * Behçet's disease\n* Availability of ≥1 technically adequate CT or MR scan with high-quality colonoscopy performed within ±1 month of imaging.\n\nExclusion Criteria:\n\n* ・Suboptimal imaging quality (e.g., low-dose artifacts, metal artifacts)\n\n  * Inadequate bowel preparation for endoscopy\n  * Incomplete examinations due to poor tolerance",true,{"count":197,"type":21},5000,"The goal of this observational, retrospective and prospective study is to develop a noninvasive disease assessment system by leveraging artificial intelligence (AI) to comprehensively analyze multi-modal imaging features, including magnetic resonance enterography (MRE) and computed tomography enterography (CTE), for the diagnosis and prognostication of digestive diseases. To this end, the investigators retrospectively enrolled imaging, endoscopic, and clinical data from 21 centers across China to construct and iteratively optimize the AI model. The model's performance will be prospectively validated in two centers, and its accuracy in lesion localization will be verified through real-world deployment in endoscopy suites.",[200,201,202,203],"Digestive Diseases","Radiology","AI (Artificial Intelligence)","Imaging",[201,203,200,205],"Artificial Intelligence","2026-04-08",{"date":208,"type":36},"2026-04-13",{"date":210,"type":36},"2025-07-01",{"date":212,"type":21},"2026-08-01",{"name":42,"class":43},{"id":215,"slug":216,"hasResults":12,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":44},"100560151","phase-4-efficacy-and-safety-of-finerenone-in-patients-with-primary-membranous-nephropathy-100560151","NCT06573411","Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy","Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy: A Prospective, Randomized, Controlled, Multicenter Clinical Study","Inclusion Criteria:\n\n* Adults (age≥18,and ≤75) with primary MN.\n* Administration of the maximum tolerable dose of ACEI\u002FARB for ≥4 weeks.\n* BP ≤140\u002F90 mmHg.\n* Urine protein content of 1.0-5.0 g\u002Fd.\n* eGFR ≥60 (CKD-EPI).\n* Postmenopausal or postoperatively infertile status or on medical contraception (considering the potential risk of thromboembolism in patients with kidney disease) in women.\n* Voluntary signing of informed consent.\n\nExclusion Criteria:\n\n* Type 1 or type 2 diabetes. Patients with a recent history of steroid-induced diabetes were eligible with renal biopsy showing no evidence of secondary diabetic nephropathy within 6 months before the screening period.\n* Patients with secondary membranous nephropathy (e.g., due to hepatitis B and C, systemic lupus erythematosus, drug therapy, malignant tumors and other secondary causes).\n* Uncontrolled arterial hypertension.\n* Treatment with glucocorticoids, immunosuppressants and\u002For biological agents in the past 6 months.\n* Treatment with any other study drug within the last month.\n* Females with a positive pregnancy screening test, lactating or planning to become pregnant in the next 24 months. Female or male patients unwilling to use contraceptive methods throughout the study.\n* A history of mental illness.\n* Laboratory tests meeting the following criteria:\n\n  1. Hemoglobin levels \\\u003C80 g\u002FL;\n  2. Platelet count \\\u003C80×109\u002FL;\n  3. Neutrophil count \\\u003C1.0×109\u002FL;\n  4. Aspartate aminotransferase (AST) or amino aminotransferase (ALT) \\>2.5 times the upper limit of normal, except in relation to the primary disease.\n* Very high-risk cases (life-threatening nephrotic syndrome or unexplained rapid deterioration of renal function).\n* Unsuitability for inclusion in the trial as judged by the investigator.",{"count":222,"type":21},116,[24],"This is a prospective, randomized, multicenter, controlled trial. One hundred sixteen patients with primary membranous nephropathy (PMN) will be randomly divided into the intervention and control groups. The intervention group will be administered maximum tolerable dose of ACEI\u002FARB and finerenone 20 mg QD. Control patients will be administered maximum tolerable dose of ACEI\u002FARB. The primary endpoint is the relative change in urinary protein content from baseline to 6 months.",[226],"Primary Membranous Nephropathy",[228,229],"finerenone","urinary protein","2026-04-03",{"date":206,"type":36},{"date":233,"type":36},"2024-09-30",{"date":235,"type":21},"2026-10-30",{"name":42,"class":43},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":244,"minAge":245,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":249,"briefSummary":250,"conditions":251,"keywords":255,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":44},"100584326","pims-vs-pgt-a-in-infertile-pcos-patients-100584326","NCT06887881","PIMS vs PGT-A in Infertile PCOS Patients","Clinical Use of Preimplantation DNA Methylation Screening (PIMS) and Preimplantation Genetics Screening (PGT-A) in Infertile PCOS Patients-A Multicenter, Prospective Randomized Non-inferior Clinical Trial","Inclusion Criteria:\n\n1. Women aged between 20 and 40 years diagnosed with PCOS according to international evidence-based guidline for assessment and management of policystic ovarian syndrome 2018.\n2. Women who plan to undergo the 1st\u002F2nd IVF\u002FICSI\u002FPGT-A treatment cycle.\n3. Women who obtain 2 or more blastocysts that have morphological score of 4BC\u002F4CB or better on Day 5of embryo culture.\n4. Culture all the cleavage stage embryos into blastocysts, conduct biopsy on all the blastocysts, and cryopreserve each blastocyst as a single embryo\n5. Agree to the thawing and transfer of a single blastocyst.\n6. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus unicornate, bicornate, or duplex); untreated uterine septum, submucous myoma, or endometrial polyp(s); or with history of intrauterine adhesions.\n2. Women who are indicated and planned to undergo preimplantation genetic testing for structural rearrangements (PGT-SR) or preimplantation genetic testing for monogenic (PGT-M).\n3. Women who use donated oocytes or sperm to achieve pregnancy.\n4. Women with contraindication for assisted reproductive technology or for pregnancy, such as undiagnosed liver disease or dysfunction (based on serum liver enzyme testing); renal disease or abnormal serum renal function; significant anemia; history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident; uncontrolled hypertension, known symptomatic heart disease; history of or suspected carcinoma including including cervical carcinoma, endometrial carcinoma, or breast carcinoma; undiagnosed vaginal bleeding and so on.\n5. Untreated hydrosalpinx according to ultrasonography test.","FEMALE","20 Years","40 Years",{"count":248,"type":21},766,[55],"This experiment has become a serious issue for two reasons: DNA methylation plays an important role during embryogenesis, global abnormal methylome reprogramming often occurs in human embryos, and DNA methylome pattern is associated with live birth rate. The endocrine metabolic disorders of polycystic ovarian syndrome (PCOS) patients may affect the epigenetic status of embryos and lead to the increase of early pregnancy loss rate in PCOS patients. However, there is still no technology using DNA methylome as an indicator in preimplantation embryo screening in PCOS patients. Our recent study showed that using Pre-implantation Methylation Screening (PIMS) can select embryos with better methylation state and euploid chromosomes. The efficiency of PIMS in PCOS patients needs further validation through randomized controlled clinical trial.\n\nThe purpose of the study is to compare whether the two groups of PCOS patients who selected embryos using PIMS and selected embryos using \"PGT-A + morphology\"had any difference in early pregnancy loss rate. This study aims to explore whether PIMS can be used as another embryo evaluation method besides \"PGT-A+morphology\" to screen good developmental potential embryos in patients with PCOS. Investigators need to clarify whether a better embryo evaluation system can be established through PIMS technology during assisted reproductive treatment for infertile PCOS couples and provide credible and effective evidence-based medical evidence for the application of PMIS technology in the field of reproductive medicine.",[252,253,254],"PGT-A","PCOS","PIMS",[254,253,252,256,257],"cumulative live birth rate","early pregnancy loss rate","2026-03-29",{"date":260,"type":36},"2026-04-02",{"date":262,"type":36},"2025-06-12",{"date":264,"type":21},"2028-12",{"name":42,"class":43},{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":275,"conditions":276,"keywords":278,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":287,"leadSponsor":289,"locationsCount":44},"100617762","efficacy-and-safety-of-reperfusion-therapy-for-minor-ischemic-stroke-in-china-100617762","NCT07322835","Efficacy and Safety of Reperfusion Therapy for Minor Ischemic Stroke in China","Efficacy and Safety of Reperfusion Therapy for Minor Ischemic Stroke in China: A Multicenter Prospective Cohort Study","Inclusion Criteria:\n\n1. Age \\>18 year\n2. Pre-stroke mRS ≤1\n3. Diagnosis of ischemic stroke, confirmed by imaging (CT or MRI)\n4. Stroke onset or last seen well (LSW) to visit ≤ 24h\n5. NIHSS ≤ 5\n6. Receive standard medication or IVT (TNK or rtPA) ± EVT, or EVT alone; for IVT beyond standard time window, initiation of treatment must occur within 4.5-24h of last seen well and ASPECTs≥7 or Perfusion lesion-ischemic core mismatch (ischemic core volume \\\u003C70mL, mismatch rate \\>1.2, mismatch volume \\>10mL or mismatch between the presence of an abnormal signal on DWI and no visible signal change on FLAIR)\n7. Patients or their eligible surrogates provided informed consent\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women\n2. Patients who already received reperfusion therapy for the current stroke before arriving at the hospital\n3. Participation in another interventional clinical trial that could interfere with the outcomes of this study",{"count":274,"type":21},5400,"Acute ischemic stroke is the most common type of stroke in China, accounting for 69.6% -72.8% of new strokes. In recent years, the proportion of mild stroke (NIHSS ≤ 5 points) has gradually increased, exceeding 50%, and the recurrence rate of stroke within one year is 13.2%, with a mortality rate of 6.3%, and 4% -10% may experience early deterioration of neurological function within 72 hours. At present, the main treatment for mild ischemic stroke is antiplatelet aggregation or anticoagulation drugs, but there are still 10% -20% of patients with residual neurological disability. There is still controversy over whether acute reperfusion therapy (including intravenous thrombolysis and endovascular intervention therapy) can improve the prognosis of such patients. In addition, it has been confirmed that beyond the time window thrombolysis is effective for selected ischemic stroke patients, but it is urgent to clarify whether mild ischemic stroke patients can benefit from receiving beyond the time window thrombolysis. Due to the limited evidence and inconsistent conclusions on the efficacy and safety of reperfusion therapy in patients with mild stroke, it is urgent to have a deeper understanding of the current status of reperfusion therapy for mild ischemic stroke in China based on real clinical data, and systematically compare the efficacy and safety of reperfusion therapy (including intravenous thrombolysis and endovascular intervention therapy) with standard drug therapy for this type of patient. This project plans to conduct a nationwide multicenter prospective cohort study to evaluate the differences in excellent neurological function prognosis (mRS ≤ 1) and symptomatic intracranial hemorrhage rate among patients with mild ischemic stroke who receive reperfusion therapy (intravenous thrombolysis ± endovascular intervention therapy) compared to standard drug therapy at 90 days, in order to guide accurate clinical decision-making. The research results have significant implications for improving the prognosis of patients with mild ischemic stroke, and will also lay an important foundation for future large-scale randomized controlled studies to explore the optimal treatment strategies for mild stroke.",[277],"Minor Ischemic Stroke",[279,280,281,282],"minor ischemic stroke","reperfusion therapy","intravenous thrombolysis","endovascular therapy","2025-12-23",{"date":285,"type":36},"2026-01-07",{"date":63,"type":21},{"date":288,"type":21},"2027-06-30",{"name":42,"class":43},{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":22,"phases":299,"briefSummary":300,"conditions":301,"keywords":303,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":313,"locationsCount":44},"100567345","phase-4-intrathecal-morphine-for-postoperative-analgesia-in-major-laparoscopic-abdominal-surgery-a-impact-scope-trial-100567345","NCT06666985","Intrathecal Morphine for Postoperative Analgesia in Major Laparoscopic Abdominal Surgery, a IMPACT-Scope Trial","Intrathecal Morphine for Postoperative Analgesia in Major Laparoscopic Abdominal Surgery (IMPACT-Scope): a Randomised, Sham-controlled, Blinded, Multicentre Clinical Trial","IMPACT-Scope","Inclusion criteria:\n\n* Age 18 years or over AND able to give informed consent (with interpreters provided where necessary)\n* Elective (i.e., planned) laparoscopic or robotic abdominal surgery within one or more of the following specialties:\n\n  * Colorectal\n  * Gynaecology\n  * Hepato-biliary (including pancreatic surgery)\n  * Upper gastrointestinal\n  * Urology\u002FRenal\n* Anticipated duration of surgery ≥ 2 hours (from knife-to-skin to end of wound closure)\n* Anticipated hospital stay ≥ 24 hours (from the end of surgery)\n\nExclusion criteria:\n\n* Allergy to study drugs\n* Anatomical factors making intrathecal injection impossible\n* Anticipated requirement for postoperative invasive ventilation\n* American Society of Anesthesiologists (ASA) Score \\\u003CIV\n* Coagulopathies (i.e. INR\\>1.3 and\u002For platelet count\\\u003C100×10\\^9\u002FL)\n* Cognitive impairment leading to inability to complete the study processes and questionnaires\n* Drugs affecting coagulation (except aspirin), which have not been suitably and timely paused preoperatively\n* Infection near the planned site of intrathecal injection\n* Ongoing sepsis\n* Patients previously included in the trial and who need to return to theatre for a new abdominal surgery\n* Pregnancy or breast feeding",{"count":171,"type":21},[24],"The goal of this clinical trial is to learn the clinical and cost effectiveness of intrathecal morphine (ITM) in addition to usual care as a postoperative pain relief strategy following major laparoscopic abdominal surgery compared with current usual care. The main questions it aims to answer are:\n\nAn enhanced analgesic technique, consisting of ITM in addition to usual care , improves the postoperative quality of recovery at day 1 after surgery by at least 6 points on the 15-item quality of recovery questionnaire (QoR-15) compared to usual care alone, in patients undergoing major laparoscopic abdominal surgery?\n\nResearchers will compare ITM + Usual care to Sham ITM + Usual Care (The sham ITM mimics the ITM procedure, but the dura is not breached) to see if ITM works to postoperative pain relief.\n\nParticipants will:\n\nReceive ITM + Usual care or Sham ITM + Usual care on surgery day Have interview with outcome assessors and complete the CRFs on the day of surgery, postoperative day 1, day 2, day 3 and up to postoperative day 30",[302],"Patients Undergoing Major Laparoscopic Abdominal Surgery",[304,305,306],"laparoscopic surgery","intrathecal morphine","quality of recovery","2025-11-19",{"date":309,"type":36},"2025-11-24",{"date":311,"type":36},"2024-12-16",{"date":160,"type":21},{"name":42,"class":43},{"id":315,"slug":316,"hasResults":12,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":321,"targetDuration":323,"studyType":103,"phases":4,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":44},"100553402","outcome-and-improvement-of-different-treatment-in-arteriosclerosis-obliterans-100553402","NCT06485622","Outcome and Improvement of Different Treatment in Arteriosclerosis Obliterans","Outcome and Improvement of Different Treatment in Arteriosclerosis Obliterans: a Prospective, Single-center, Observational Study","Inclusion Criteria:\n\n1. Age 18 years or older, gender is not limited.\n2. Patients diagnosed with arteriosclerosis obliterans.\n3. Rutherford stages 2-6.\n4. When there are multiple stenosis lesions, the treatment of the most severe lesion is included.\n5. Patients with at least one arterial occlusion ( iliac, femoral, popliteal, anterior tibial, posterior tibial, and\u002For peroneal artery) of the lower extremity were included.\n\nExclusion Criteria:\n\n1. Malignant tumor\n2. Alzheimer's disease\n3. Blood disease or bleeding tendency\n4. Heart Failure Grade III \\~ IV\n5. Pregnancy or lactation\n6. An above-knee-below-knee amputation has been performed\n7. Unable to accept therapeutic function tests\n8. Life expectancy is less than six months\n9. Combined with other diseases affecting walking\n10. Cardiovascular and cerebrovascular events occurred within 3 months, including non-fatal myocardial infarction, unstable angina, stable angina, non-fatal ischemic stroke and hemorrhagic stroke\n11. Patients with significant abnormal liver and renal function that the investigators judged to be clinically significant",{"count":322,"type":21},400,"3 Years","This study is a prospective, single-center, observational study. In this study, we aim to evaluate the clinical outcome and cost-effectiveness of different treatments of lower extremity arterial occlusive disease. It is expected to include about 400 patients diagnosed with lower extremity arterial occlusive disease in our center from July 2024 to July 2026. All enrolled patients will be followed for three years. All patients diagnosed with arteriosclerosis obliterans (ASO) and all treatment techniques were included in this study. The primary outcomes include the Efficacy and Safety End Points of each techniques.",[326],"Arteriosclerosis Obliterans","2025-08-05",{"date":329,"type":36},"2025-08-08",{"date":331,"type":36},"2024-07-01",{"date":333,"type":21},"2029-07",{"name":42,"class":43},{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":244,"minAge":245,"maxAge":343,"enrollmentInfo":344,"targetDuration":4,"studyType":22,"phases":346,"briefSummary":347,"conditions":348,"keywords":351,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":44},"100597980","gnrh-agonist-pretreatment-duration-and-letrozole-supplementation-in-frozen-embryo-transfer-for-adenomyosis-patients-100597980","NCT07065539","GnRH Agonist Pretreatment Duration and Letrozole Supplementation in Frozen Embryo Transfer for Adenomyosis Patients","The Impact of Duration of Gonadotropin-Releasing Hormone Agonist Pretreatment and Letrozole Supplementation on Pregnancy Outcomes in Frozen-Thawed Embryo Transfer Cycles for Patients With Adenomyosis: A 2 by 2 Factorial Multicenter, Randomized Controlled Trial","GOLD-FET","Inclusion Criteria:\n\n* Sonographically diagnosed adenomyosis via transvaginal ultrasound;\n* Candidates scheduled for frozen single blastocyst (Day5, Day6) transfer\n* Age 20-38 years\n* Previous embryo transfer attempts: ≤2 cycles\n\nExclusion Criteria:\n\n* Patients diagnosed with Recurrent pregnancy loss, Autoimmune disorders (e.g., systemic lupus erythematosus), Uterine fibroids ≥5 cm, Cervical incompetence, Cesarean scar niche\n* History of Myomectomy and\u002For adenomyosis lesion excision, Cervical conization\n* Patients presenting with Congenital Müllerian anomalies (unicornuate uterus, septate uterus, etc.), Endometrial atypical hyperplasia, malignancy or defects\n* Sperm retrieval method: Micro-TESE (microdissection testicular sperm extraction)\n* Fertilization method: Rescue ICSI\n* Endometrial thickness \\\u003C7 mm, Intrauterine adhesions, Intrauterine fluid\n* Contraindications to exogenous hormone administration\n* Use of GnRH within 3 months prior to enrollment","38 Years",{"count":345,"type":21},432,[55],"This randomized clinical trial aims to assess the comparative effectiveness of different pre-treatment protocols prior to frozen embryo transfer (FET) among women with adenomyosis, providing evidence-based guidance for clinical decision-making. The main questions it aims to answer are:\n\nDoes the protocol involving two doses of gonadotropin-releasing hormone agonist (GnRH-a) pretreatment result in a higher live birth rate compared to one dose of GnRH-a pretreatment in women with adenomyosis undergoing frozen embryo transfer? Does the protocol involving GnRH-a with letrozole supplementation result in a higher live birth rate compared to GnRH-a monotherapy in women with adenomyosis undergoing frozen embryo transfer? Eligible participants will undergo screening before endometrial preparation for FET, following which they will be randomly assigned to one of four groups: GnRH-a-1M, GnRH-a-2M, GnRH-a+LE-1M or GnRH-a+LE-2M. In the GnRH-a-1M group, participants will be pre-treated with one dose GnRH agonist before endometrial preparation. In the GnRH-a-2M group, participants will be pre-treated with two doses GnRH agonist before endometrial preparation. In the GnRH-a+LE-1M group, participants will be pre-treated with one dose GnRH agonist and letrozole 28 days before endometrial preparation. In the GnRH-a+LE-2M group, participants will be pre-treated with two doses GnRH agonist, along with daily 2.5 mg letrozole for 28 days since the first injection of GnRH agonist before endometrial preparation. After pre-treament, all participants will return for endometrial preparation in artificial cycles.",[349,350],"Adenomyosis of Uterus","Frozen Embryo Transfer (FET)",[352,353,354,355,356],"adenomyosis","embryo transfer","GnRH-a","letrozole","pre-treament","2025-07-14",{"date":359,"type":36},"2025-07-15",{"date":361,"type":21},"2025-07-20",{"date":363,"type":21},"2027-12",{"name":42,"class":43},{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":244,"minAge":18,"maxAge":373,"enrollmentInfo":374,"targetDuration":4,"studyType":22,"phases":376,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":389,"locationsCount":44},"100575087","effectiveness-of-a-lifestyle-intervention-for-pregnant-women-with-abnormal-glucose-metabolism-in-early-pregnancy-eagm-trial-100575087","NCT06767722","Effectiveness of a Lifestyle Intervention for Pregnant Women With Abnormal Glucose Metabolism in Early Pregnancy: EAGM Trial","Effectiveness of a Lifestyle Intervention for Pregnant Women With Abnormal Glucose Metabolism in Early Pregnancy: EAGM Randomized Controlled Trial","EAGM","Inclusion Criteria:\n\n* Over 18 years of age.\n* Able to provide informed consent.\n* Confirmed viable pregnancy on a nuchal translucency scan done between 11+0 and 13+6 weeks.\n* Singleton pregnancies.\n* An abnormal glucose metabolism determined by a blood test performed before 14 weeks, defined as FPG 5.1-6.9mmol\u002FL and\u002For HbA1c 5.7-6.4%.\n\nExclusion Criteria:\n\n* Pregestational diabetes (diagnosed as diabetes mellitus before pregnancy, or FPG≥7.0mmol\u002FL, or HbA1c≥6.5% at the first prenatal visit), impaired fasting glucose or impaired glucose tolerance diagnosed before pregnancy.\n* Plan for termination of pregnancy due to fetal anomaly identified at the first trimester scan.\n* Use of medications known to interfere with glucose metabolism (e.g. corticosteroids, antipsychotic drugs) at the time of randomisation.\n* Any other physical (serious medical conditions such as cancer, organ failure, epilepsy, paraplegia, disability) or psychological condition (e.g. learning difficulties, serious mental illness) that is likely to interfere with the conduct of the trial according to evaluation by the trial monitoring group.\n* Women currently with hyperemesis gravidarum leading to dehydration or requiring hospitalization. If persisting vomiting resolves, the patient may be reassessed for inclusion in the trial up to and including 14+6 weeks of gestation, providing all other inclusion and exclusion criteria are met.","55 Years",{"count":375,"type":21},3430,[55],"This is a multicentre, parallel-group, open-label, pragmatic, randomised-control trial of early lifestyle intervention versus routine prenatal care by random allocation (1:1) in women with early abnormal glucose metabolism (EAGM) to compare the incidence of large-gestational age and preterm birth between two groups. The investigators aim to assess the effectiveness of early lifestyle interventions and to provide evidence for the optimal standard management for Chinese women with EAGM.",[379,380,381,382,383],"Early Pregnancy","Fasting Plasma Glucose","Hemoglobin A1c Protein, Human","Lifestyle Intervention","Adverse Pregnancy Outcomes","2025-06-25",{"date":210,"type":36},{"date":387,"type":36},"2025-04-16",{"date":288,"type":21},{"name":42,"class":43},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":397,"targetDuration":102,"studyType":103,"phases":4,"briefSummary":398,"conditions":399,"keywords":401,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":44},"100594056","efficacy-of-the-ranger-drug-coated-balloon-in-treating-btk-lesions-in-patients-with-clti-100594056","NCT07014475","Efficacy of the Ranger Drug-Coated Balloon in Treating BTK Lesions in Patients With CLTI","Efficacy of the Ranger Drug-Coated Balloon in Treating Below-the-Knee Lesions in Patients With Chronic Limb-Threatening Ischemia","Inclusion Criteria:\n\n1. Age ≥ 18 years, gender is not limited\n2. The patient agreed to participate in the CEIBA study and signed the written informed consent\n3. Diagnosis of chronic limb-threatening ischemia (Rutherford category 4-6)\n4. Gangrene involving any part of the lower extremities or feet, with exclusion of patients who have:\n\n   4.1 Pure venous ulcers 4.2 Pure traumatic wounds 4.3 Acute limb ischemia (symptoms present for 2 weeks or less) 4.4 Embolic disease 4.5 Non-atherosclerotic chronic lower extremity vascular diseases (e.g., vasculitis, Buerger's disease, radiation arteritis)\n5. Outflow Tract Requirement: At least one direct or indirect, unobstructed outflow vessel in the submalleolar segment of the target limb planned for revascularization.\n6. Lesion Type:\n\n6.1 Unobstructed blood flow in the suprapopliteal access pathway (including inflow vessels that have been recanalized via staged or concurrent endovascular intervention or hybrid surgery).\n\n6.2 Sub-knee stenotic lesions ≥ 5 cm in length with ≥ 70% diameter reduction. 6.3 Sub-knee occlusive lesions ≥ 1 cm in length. 6.4 Two separate lesions with a minimum 3 cm interval between them may be considered as a single lesion for study inclusion purposes.\n\nExclusion Criteria:\n\n1. Presence of life-threatening diseases or comorbidities with an expected life expectancy of less than 1 year.\n2. Concurrent participation in another interventional clinical trial requiring informed consent.\n3. Diagnosis of Alzheimer's disease.\n4. Hematologic disorders or known bleeding tendency.\n5. Contraindications to antiplatelet or anticoagulant therapy.\n6. Known allergy to contrast agents that cannot be managed with standard premedication (e.g., steroids).\n7. Deficiency or dysfunction of protein C, protein S, or antithrombin III (ATIII).\n8. New York Heart Association (NYHA) Class III or IV heart failure.\n9. Pregnancy or lactation.\n10. Prior suprapatellar or infrapatellar amputation of the target limb.\n11. Presence of aneurysm, perforation, dissection, or other target vessel injury requiring intervention.\n12. Presence of other comorbid conditions (unrelated to the index disease) that affect walking function.\n13. History of cardiovascular events within the past 3 months, including nonfatal myocardial infarction, unstable angina, stable angina, nonfatal ischemic stroke, or hemorrhagic stroke.\n14. Clinically significant liver or renal dysfunction, as determined by the investigator.\n15. Any other condition that, in the opinion of the investigator, would interfere with study treatment or functional assessments.",{"count":171,"type":21},"This is a prospective, multicenter, observational study designed to evaluate the clinical outcomes of the Ranger™ SL paclitaxel-coated balloon, a type of drug-coated balloon (DCB), in the treatment of below-the-knee (BTK) lesions in patients with chronic limb-threatening ischemia (CLTI) in China. All enrolled patients will be followed for six months. Patients diagnosed with CLTI who undergo treatment with the Ranger DCB will be included in the study. The primary outcome is the incidence of major adverse events (MAEs).",[400],"Chronic Limb Threatening Ischemia",[402,403,404],"chronic limb threatening ischemia","below the knee","drug-coated balloon","2025-06-03",{"date":407,"type":36},"2025-06-11",{"date":409,"type":21},"2025-06-30",{"date":411,"type":21},"2029-01-01",{"name":42,"class":43},{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":17,"minAge":246,"maxAge":75,"enrollmentInfo":420,"targetDuration":4,"studyType":22,"phases":422,"briefSummary":423,"conditions":424,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":432,"locationsCount":4},"100589201","clinical-trial-of-vildagliptin-in-early-parkinsons-disease-100589201","NCT06951334","Clinical Trial of Vildagliptin in Early Parkinson's Disease","VERY-PD","Inclusion Criteria:\n\n* 1: Patients aged 40 to 75 years who were diagnosed with Parkinson's disease according to the UK Brain Bank criteria within the past three years.\n\n  2: Participants must have received an optimized and stable dopaminergic medication regimen (dopamine agonists, levodopa, or monoamine oxidase B \\[MAOB\\] inhibitors, or combinations of these medications) determined by the study site investigators for at least one month prior to the baseline initiation of the trial drug, with the expectation that the participants will be able to continue this regimen for at least six months.\n\n  3: Sign the informed consent form\n\nExclusion Criteria:\n\n* 1: The key exclusion criterion is a score of at least 3 on the Hoehn and Yahr scale (ranging from 1 to 5, with higher scores indicating more severe disability), which indicates that Parkinson's disease has led to at least mild to moderate bilateral motor involvement due to some postural instability.\n\n  2: Presence of motor fluctuations or motor complications (or both).\n\n  3: The presence of severe psychiatric disorders, such as severe (treatment-resistant) anxiety, depression, or schizophrenia, that cannot be effectively controlled by medication.\n\n  4: Atypical or secondary Parkinsonism\n\n  5: A score of 18 or lower on the Montreal Cognitive Assessment (MoCA) (range: 0 to 30, with a score of 26 or higher indicating normal cognitive function), indicating at least mild cognitive impairment.\n\n  6: Diabetes mellitus (Type 1 and Type 2), as well as prior treatment with dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide-1 (GLP-1) receptor agonists.\n\n  7: Individuals with severe renal impairment (creatinine clearance \\\u003C30 ml\u002Fmin), active liver disease, history of drug or alcohol abuse, idiopathic pancreatitis, chronic pancreatitis, or a history of pancreatectomy.\n\n  8: Individuals with a body mass index (weight in kilograms divided by the square of height in meters) less than 18.5, or those with a weight change exceeding 5 kilograms within the 3 months prior to screening.\n\n  9: Currently participating in other relevant clinical trials involving pharmacological or surgical treatments.\n\n  10: Other situations where the investigator believes that the subject is unable to participate in or cooperate with the entire assessment process of the clinical trial.",{"count":421,"type":21},66,[55],"Investigating the efficacy of Vildagliptin in delaying the progression of Parkinson's disease.",[425],"Parkinson's Disease","2025-04-26",{"date":428,"type":36},"2025-04-30",{"date":430,"type":21},"2025-06-01",{"date":160,"type":21},{"name":42,"class":43},{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":439,"targetDuration":4,"studyType":22,"phases":441,"briefSummary":442,"conditions":443,"keywords":447,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":450,"lastUpdatePostDateStruct":451,"startDateStruct":452,"completionDateStruct":453,"leadSponsor":454,"locationsCount":4},"100587548","research-on-the-safety-and-efficacy-of-intraoperative-radiation-therapy-in-malignant-cerebral-tumor-100587548","NCT06929819","Research on the Safety and Efficacy of Intraoperative Radiation Therapy in Malignant Cerebral Tumor","Inclusion Criteria:\n\n* 18-75 years old, non-pregnant or lactating women\n* KPS ≥60\n* MRI and CT of the brain with contrast should be considered for diagnosis of high-grade glioma or other malignant brain tumors\n* No other underlying diseases that affect survival time, follow-up or quality of life, and no other serious organic lesions\n* Not receive radiotherapy, chemotherapy and other treatment methods for intracranial lesions in the past;\n* Tumor located supratentorium, and the position should ensure that the tumor resection volume is more than 90%;\n* The required dose of standard radiotherapy exceeds normal tissue tolerance\n* No related contraindications such as intraoperative radiotherapy and craniotomy.\n\nExclusion Criteria:\n\n* Refuse to undergo craniotomy or radiation therapy;\n* The postoperative paraffin pathological results were not high-grade gliomas or other cranial malignant tumors;\n* Refuse to participate in the clinical trial after informed consent without the above exclusion criteria.",{"count":440,"type":21},200,[55],"According to the latest national cancer statistics released by the National Cancer Center in February 2022, intracranial tumors account for about 60%-70% of the more than 3.5 million cancer patients, and the morbidity and mortality remain high. Intracranial malignant tumors have become a problem that needs to be solved urgently because of their early recurrence, rapid progression, and short survival, and intracranial malignant tumors include high-grade gliomas, metastases, lymphomas, etc.\n\nGlioblastoma (GB) is the most common primary malignancy in the adult central nervous system, accounting for about 57% of all gliomas and 48% of all primary weighted nervous system malignancies. At present, the standard treatment for glioblastoma is mainly surgical treatment, supplemented by postoperative concurrent chemoradiotherapy and adjuvant chemotherapy, but the prognosis of patients is still poor, with a one-year survival rate of 40.6%, a five-year survival rate of only 5.6%, and an average survival time of 12-15 months.\n\nFor patients diagnosed with intracranial malignancies (including high-grade glioma, metastases, lymphoma, etc.), multimodal image-guided microsurgery combined with postoperative chemoradiotherapy recommended by the guidelines, and intraoperative radiotherapy with tumor bed radiation therapy to achieve targeted and precise tumor treatment, thereby improving the prognosis of patients (including progression-free survival and median overall survival, etc.)",[444,445,446],"Glioblastoma","Brain Tumor, Primary","Brain Tumor - Metastatic",[448,449],"Brain Tumor","Intraoperative Radiation Therapy","2025-04-15",{"date":387,"type":36},{"date":430,"type":21},{"date":187,"type":21},{"name":42,"class":43},{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":195,"sex":17,"minAge":246,"maxAge":75,"enrollmentInfo":463,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":464,"conditions":465,"keywords":467,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":477,"locationsCount":44},"100574746","comparison-of-multi-omics-models-for-early-nasopharyngeal-carcinoma-screening-cfdna-methylation-ebv-dna-and-serological-double-antibodies-detection-100574746","NCT06763289","Comparison of Multi-omics Models for Early Nasopharyngeal Carcinoma Screening: CfDNA Methylation, EBV DNA, and Serological Double-antibodies Detection","Comparison Between Multi-omics Models Including DNA Methylation in CfDNA, Quantitative Determination of Epstein-Barr Virus Nucleic Acid and Serological Double Antibody Detection in Early Screening of Nasopharyngeal Carcinoma","PROFOUND-NPC","Inclusion Criteria for Case Arm Participants:\n\n1. 40-74 years old\n2. Clinically and\u002For pathologically diagnosed cancer\n3. No prior or undergoing any systemic or local antitumor therapy, including but not limited to surgical resection, radiochemotherapy, endocrinotherapy, targeted therapy, immunotherapy, interventional therapy, etc.\n4. Able to provide a written informed consent and willing to comply with all part of the protocol procedures\n\nExclusion Criteria for Case Arm Participants:\n\n1. Pregnancy or lactating women\n2. Known prior or current diagnosis of other types of malignancies comorbidities\n3. Severe acute infection (e.g. severe or critical COVID-19, sepsis, etc.) or febrile illness (body temperature of ≥ 38.5 °C) within 14 days prior to screen\n4. Recipients of organ transplant or prior bone marrow transplant or stem cell transplant\n5. Recipients of blood transfusion within 30 days prior to screen\n6. Recipients of therapy in past 14 days prior to screen, including oral or IV antibiotics, glucocorticoid, azacitidine, decitabine, procainamide, hydrazine, arsenic trioxide\n7. Unsuitable for this trial determined by the researchers\n\nInclusion Criteria for Control Arm Participants:\n\n1. 40-74 years old\n2. Without confirmed cancer diagnosis\n3. Able to provide a written informed consent and willing to comply with all part of the protocol procedures\n\nExclusion Criteria for Control Arm Participants:\n\n1. Pregnancy or lactating women\n2. Known prior or current diagnosis of other types of malignancies comorbidities\n3. Severe acute infection (e.g. severe or critical COVID-19, sepsis, etc.) or febrile illness (body temperature of ≥ 38.5 °C) within 14 days prior to screen\n4. Recipients of organ transplant or prior bone marrow transplant or stem cell transplant\n5. Recipients of blood transfusion within 30 days prior to screen\n6. Recipients of therapy in the past 14 days prior to screen, including oral or IV antibiotics, glucocorticoid, azacitidine, decitabine, procainamide, hydrazine, arsenic trioxide\n7. Unsuitable for this trial determined by the researchers",{"count":171,"type":21},"This study focus on nasopharyngeal carcinoma, a cancer type with Chinese characteristics, analyze the early screening detection performance of nasopharyngeal carcinoma in the multi-cancer early screening model, and compare the performance differences among multi-omics models such as nasopharyngeal carcinoma-specific DNA methylation and fragmentome in the multi-cancer early screening model and the clinically routinely conducted Epstein-Barr virus (EBV) nucleic acid quantification (EBV DNA) test and serological double antibody (double antibodies of EBNA1-IgA and VCA-IgA) test. It suggests that compared with EBV DNA quantification and double antibody tests, in patients with nasopharyngeal carcinoma, multi-omics models such as DNA methylation can avoid false negatives, improve sensitivity, and increase the detection rate of early-stage nasopharyngeal carcinoma; in patients without nasopharyngeal carcinoma, multi-omics models such as DNA methylation can avoid false positives, improve specificity, and avoid unnecessary over-diagnosis.",[466],"Nasopharyngeal Carcinoma (NPC)",[468,469,470],"cell-free DNA","methylation","cancer early detection","2025-01-02",{"date":473,"type":36},"2025-01-08",{"date":475,"type":36},"2024-12-25",{"date":288,"type":21},{"name":42,"class":43},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":482,"acronym":483,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":17,"minAge":485,"maxAge":4,"enrollmentInfo":486,"targetDuration":487,"studyType":103,"phases":4,"briefSummary":488,"conditions":489,"keywords":491,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":44},"100568536","high-quality-evidence-of-guangzhou-lupus-nephritis-cohort-hope-cohort-100568536","NCT06682507","High Quality Evidence of Guangzhou Lupus Nephritis Cohort (HOPE Cohort)","HOPE","Inclusion Criteria:\n\nPatients who had biopsy proven lupus nephritis in The First Affiliated Hospital of Sun Yat-sen University\n\nExclusion Criteria:\n\n* less than 14 years old\n* refused to give written consent","14 Years",{"count":197,"type":21},"30 Years","The goal of this observational study is to learn about the long-term renal and patient's survival of lupus nephritis (LN) patients in China. The main question it aims to answer is:\n\nDoes the renal and patient's survival improved in the long term period? Participants who had renal biopsy proven lupus nephritis in one hospital will be followed up.",[490],"Lupus Nephritis (LN)",[492,493,494,495],"lupus","lupus nephritis","outcomes","end stage kidney disease","2024-11-08",{"date":498,"type":36},"2024-11-12",{"date":500,"type":36},"1996-01-01",{"date":502,"type":21},"2050-12-31",{"name":42,"class":43},{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":510,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":513,"conditions":514,"keywords":516,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":4},"100560088","the-predictive-value-of-mri-for-adult-type-diffuse-gliomas-100560088","NCT06572592","The Predictive Value of MRI for Adult-type Diffuse Gliomas","The Prognostic Value of Preoperative Multi-model Diffusion MRI in Predicting Ki-67 Proliferation for Adult-type Diffuse Gliomas","MRI; glioma;","Inclusion Criteria:\n\n* First diagnosis of glioma, with no preoperative radiotherapy or chemotherapy.\n* Underwent multiparametric MRI examination in our hospital before surgery.\n* Tumor resection or biopsy was performed within 3 weeks after MRI examination.\n* Pathological examination confirmed glioma.\n\nExclusion Criteria:\n\n* Inability to cooperate during MRI examination, resulting in poor image quality that prevents image analysis.\n* Surgery or biopsy specimens were unqualified and could not be analyzed pathologically.",{"count":440,"type":21},"The goal of this observational study is to learn about the diagnostic value of preoperative MRI examination for adult-type diffuse gliomas. The main question it aims to answer is:\n\n* Can preoperative MRI examination noninvasively predict genotype of gliomas?\n* Can preoperative MRI examination noninvasively predict the overall survival of gliomas?\n* Can preoperative MRI examination noninvasively predict Ki-67 proliferation status?",[515],"Glioma",[517,518,519,520],"glioma","MRI","IDH","Ki-67","2024-08-25",{"date":523,"type":36},"2024-08-27",{"date":525,"type":21},"2024-08-22",{"date":527,"type":21},"2030-05",{"name":42,"class":43},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":535,"enrollmentInfo":536,"targetDuration":4,"studyType":22,"phases":538,"briefSummary":539,"conditions":540,"keywords":542,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":44},"100515365","research-on-the-safety-and-efficacy-of-blocking-dural-blood-supply-in-glioblastoma-patients-100515365","NCT05990556","Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients","Inclusion Criteria:\n\n* Imaging or needle biopsy pathologically diagnosed as glioblastoma\n* Patients have not previously received radiotherapy, chemotherapy and other treatment modalities for intracranial lesions\n* There are no related contraindications such as neurovascular intervention and craniotomy\n\nExclusion Criteria:\n\n* The patient's initial imaging diagnosis was glioblastoma, and the postoperative pathology confirmed nonglioblastoma\n* The patient has other underlying medical conditions that affect survival time\n* The patient had other underlying medical conditions that affected follow-up or quality of life assessment\n* Patients do not have the above exclusion criteria and refuse to participate in clinical trials after informed consent","70 Years",{"count":537,"type":21},20,[55],"Glioblastoma is the most common primary malignancy of the central nervous system with a very poor prognosis. Most of the immunotherapies that have made significant breakthroughs in the treatment of other tumors in recent years are unsatisfactory in the application of glioblastoma, which is mainly inseparable from the highly inhibitory immune microenvironment formed by the latter. Therefore, how to change this \"immune desert\" and better activate immune effector cells to play an anti-tumor effect is currently a hot spot in glioma immune research. In recent years, there has been continuous research support that the myeloid cells of the central nervous system are partly derived from the bone marrow of the skull, and there is a special channel connection between the skull and the dura mater, through which immune cells can be transported. This suggests that some of the tumor-associated macrophages recruited in the glioblastoma microenvironment may be passed through the dura mater. In previous animal experiments, we blocked the main blood supply to the dura mater by ligating the bilateral external carotid arteries of mice, cutting off the potential supply of dura mater to suppressor myeloid cells in the lesion. The results showed that after ligation of bilateral external carotid arteries, the survival period of tumor-forming mice was significantly prolonged and the prognosis was improved. The proportion of myeloid cells in the tumor microenvironment of mice decreased significantly, and the expression of tumor suppressor molecules such as arginase Arg1 decreased, indicating that the improvement of mouse prognosis was closely related to the proportion and phenotypic changes of myeloid cells after dural blood supply blockade. The meningeal lymphatic system of the human central nervous system has been shown to be an important part of the immune system, while the external carotid artery system, the main source of blood supply to the dura, carries abundant immune cells that ooze out to the dura mater through the endothelial window hole of the dural blood vessel, which is an important source of dural immune cells. In the glioblastoma immune microenvironment, the source of immune cells includes dural branches from the external carotid artery system in addition to branches of the internal carotid artery system. Therefore, for patients diagnosed with glioblastoma, this study involves embolization of the dural branch of the external carotid artery system (bilateral middle meningeal artery) to block the dural blood supply before craniotomy. At the same time, microsurgery under multimodal image navigation was used to remove the tumor. It is expected to be effective in reducing the proportion of myeloid suppressor cells in the tumor microenvironment, slowing the growth rate of residual tumor cells, and prolonging the tumor-free progression and survival of patients.",[444,541],"Meningeal Arteries",[543],"glioblastoma","2024-07-22",{"date":546,"type":36},"2024-07-24",{"date":548,"type":36},"2024-05-11",{"date":550,"type":21},"2028-09-01",{"name":42,"class":43},{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":4,"eligibilityCriteria":558,"healthyVolunteers":195,"sex":17,"minAge":18,"maxAge":559,"enrollmentInfo":560,"targetDuration":4,"studyType":103,"phases":4,"briefSummary":562,"conditions":563,"keywords":566,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":571,"lastUpdatePostDateStruct":572,"startDateStruct":574,"completionDateStruct":576,"leadSponsor":577,"locationsCount":44},"100550859","neurophenotype-predicts-cd-disease-progression-100550859","NCT06452550","Neurophenotype Predicts CD Disease Progression","Multimodal MRI-based Neurophenotype Reflecting Brain-gut Interactions to Predict Intestinal Disease Progression in Patients With Crohn's Disease","Inclusion Criteria:\n\n* (a) CD patients aged 18-45 years; (b) the completion of multimodal brain MRI and administration of psychological questionnaires; (c) MR enterography (MRE), ileocolonoscopy, and blood or faecal samples, collection within one week of brain MRI; (d) a follow-up of at least six months for patients without disease progression; and (e) right-handedness.\n\nExclusion Criteria:\n\n* (a) recent use of antibiotics, probiotics, or prebiotics within three months prior to inclusion; (b) history of neurosurgery, cerebrovascular disease, or brain trauma; (c) use of central nervous system drugs or antidepressants within three months prior to inclusion; (d) identification of brain lesions on MR scan; (e) claustrophobia; or (f) presence of metal implants.","45 Years",{"count":561,"type":21},500,"The goal of this observational study is aimed to develop a novel multimodal neuroimaging-based model to characterize the neurophenotype of Crohn's Disease patients and assess its ability for predicting disease progression, using multiomics data to interpret the model.\n\nParticipants will be followed-up of at least six months for patients without disease progression to assess the relationship between neurophenotype and intestinal outcomes.",[564,565],"Radiomics","Multi-omics",[567,568,569,570],"Abdominal MRI","Magnetic Resonance Imaging","Crohn's disease","Brain\u002Fgut interaction","2024-06-05",{"date":573,"type":36},"2024-06-11",{"date":575,"type":36},"2021-05-01",{"date":430,"type":21},{"name":42,"class":43},{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":4,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":75,"enrollmentInfo":585,"targetDuration":4,"studyType":22,"phases":587,"briefSummary":588,"conditions":589,"keywords":590,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":602,"locationsCount":44},"100478749","phase-4-clinical-study-of-rituximab-combined-with-corticosteroids-or-rituximab-monotherapy-in-the-treatment-of-primary-membranous-nephropathy-100478749","NCT05514015","Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy","A Prospective, Randomized, Multicenter Clinical Trial Comparing the Efficacy and Safety of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in Primary Membranous Nephropathy","Inclusion Criteria\n\n1. Men and women aged 18-75 years;\n2. Patients diagnosed as primary membranous nephropathy (PMN) by renal biopsy;\n3. After treatment with ACE inhibitors or ARBs for at least 3 months, the following two points were met (unless intolerance to ACE inhibitors or ARBs, contraindications, hypotension that may cause side effects, or the investigator judged that the patient was not suitable for RAS inhibitors):\n\n(1) Those who have an average 24-hour urine protein ≥ 3.5g twice a week, or an average 24-hour urine protein ≥ 5g twice in 14 days, the requirement of RASi for at least 3 months is not required (2) Blood pressure≤ 130\u002F80mmHg, 4. Glomerular filtration rate (eGFR) ≥30mL\u002Fmin\u002F1.73m2 (calculated according to the CKD-EPI formula) 5. If female, must be postmenopausal or postoperatively infertile or on medical contraception (considering the potential risk of thromboembolism in patients with kidney disease); 6. Subjects voluntarily signed the informed consent form;\n\nExclusion Criteria:\n\n1. Patients with type 1 diabetes mellitus or type 2 diabetes mellitus complicated with diabetic nephropathy. Patients with a recent history of steroid-induced diabetes were eligible if renal biopsies show no evidence of secondary diabetic nephropathy within 6 months before the screening period\n2. Patients with secondary membranous nephropathy (such as hepatitis B and C, systemic lupus erythematosus, drug therapy, malignant tumors and other secondary causes);\n3. Previous treatment with rituximab, steroids, alkylating agents, calcineurin inhibitors, synthetic ACTH, mycophenolate (MMF), and azathioprine;\n4. Receipt of any other study medication (within the last month);\n5. Suspected or known allergy or immune reaction to rituximab, corticosteroids or any of their components (including excipients);\n6. Active infection, such as active hepatitis B or hepatitis C, tuberculosis (evidence of active tuberculosis infection within 1 year), or human immunodeficiency virus HIV infection (positive for anti-HIV antibodies), etc.\n7. A history of immunodeficiency, including other acquired or congenital immunodeficiency diseases, or organ transplantation;\n8. Females with a positive pregnancy screening test or lactating or planning to become pregnant in the next 24 months. Female or male patients who were unwilling to use contraceptive methods throughout the study;\n9. A history of mental illness;\n10. Laboratory tests that meet the following criteria need to be excluded:\n\n(1) Hemoglobin\\\u003C80g\u002FL; (2) Platelet \\\u003C 80×109\u002FL; (3) Neutrophil \\\u003C1.0×109\u002FL; (4) Aspartate aminotransferase (AST) or amino aminotransferase (ALT) \\> 2.5× upper limit of normal except in relation to the primary disease; 11. Very high-risk patients: presenting with life-threatening nephrotic syndrome, or unexplained rapid deterioration of renal function 12. Any patient judged by the investigator to be unsuitable for inclusion in the trial.",{"count":586,"type":21},78,[24],"This was a prospective, randomized, multicenter clinical trial. Seventy-eight patients with primary membranous nephropathy (PMN) were randomly divided into intervention or control group. Intervention group was given rituximab combined with corticosteroids in induction therapy and the control group was given rituximab monotherapy. After 6 months, patients who had decreased 24h urinary protein by \\> 25% but did not achieve CR were given rituximab maintenance therapy. The complete response rate at 12 months was measured.",[226],[591,592,593,594,595],"rituximab","Primary membranous nephropathy","rituximab combined with corticosteroids","safety","remission","2024-04-01",{"date":598,"type":36},"2024-04-02",{"date":600,"type":21},"2024-03-29",{"date":160,"type":21},{"name":42,"class":43},""]